Thane Wettig compensation by year
KYNTRA BIO Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $665,000 | $665,000 |
| Bonus | $0 | $0 |
| Stock awards | $284,690 | $0 |
| Option awards | $1,231,568 | $846,023 |
| Non-equity incentive | $434,611 | $580,545 |
| Pension and deferred compensation | $0 | $0 |
| All other | $26,244 | $22,274 |
| Total | $2,642,113 | $2,113,842 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: KYNTRA BIO, INC. DEF 14A filed April 27, 2026, accession 0001193125-26-182044, and prior-year filings.
How this page was built: the KYNTRA BIO, INC. filed document, accession 0001193125-26-182044. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 3,735 | $32,793 | — |
| PSU | 675 | $5,926 | — |
| Option | 187 | — | $390.00 |
| Option | 42,250 | — | $16.27 |
| Option | 18,765 | — | $42.88 |
| Option | 5,249 | — | $44.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in KYNTRA BIO, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2025 proxy (filed April 27, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-06 | Tax withholding | — | 209 | $8.55 | 26,796 |
| 2026-06-06 | Tax withholding | — | 198 | $6.71 | 27,005 |
| 2026-05-14 | Purchase | — | 2,800 | $7.09 | 27,203 |
| 2026-05-14 | Purchase | — | 2,800 | $7.09 | 27,203 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
KYNTRA BIO’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Thane Wettig · this page | Chief Executive Officer and Director | $2,113,842 |
| Christine Chung | former Senior Vice President, China Operations | $1,181,108 |
| David DeLucia | Chief Financial Officer | $1,110,999 |
Board service
KYNTRA BIO board · FY2024–FY2025How this board is paid
Company policy: KYNTRA BIO pays directors a $50,000 cash retainer. As stated in KYNTRA BIO's FY2025 proxy.
The full KYNTRA BIO compensation record
free company briefThis page is one person within KYNTRA BIO's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the KYNTRA BIO proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order KYNTRA BIO's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are KYNTRA BIO's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.